Evercore ISI lowered the firm’s price target on Janux Therapeutics (JANX) to $23 from $25 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux announces development candidate nomination under Bristol Myers collab
- Janux Therapeutics price target lowered to $80 from $100 at Truist
- Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
- Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating
- Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald